HSB-510

HSB-510 is a **first-in-class bifunctional dual inhibitor** of phosphoinositide 3-kinase delta (**PI3Kδ**) and histone deacetylase 6 (**HDAC6**), encapsulated in a proprietary Quatramer-based nanoparticle formulation. The drug is designed for targeted delivery to tumor cells, demonstrating **potent anti-proliferative activity against multiple breast cancer cell lines** and effective tumor growth inhibition in mouse models, via downregulation of signaling intermediates including phospho-AKT, phospho-ERK, and c-Myc. Preclinical studies specifically highlight activity in triple negative breast cancer (TNBC) and suggest potential for other MYC-driven cancers. HSB-510 achieves high tumor selectivity, enhanced bioavailability, and controlled release, and is being developed primarily by Hillstream BioPharma as a novel therapy for MYC-dependent tumors and solid tumors[1][2][4][7][9][12].

Brand names

HSB-510HSB510HSB 510

Other names

HSB-510HSB510HSB 510